Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Covid 19: Will pain-free, at-home screening tests be our salvation?

The world’s best defence against the spread of COVID-19 in 2021 will not be a vaccine, medical experts now say. Instead, it will be the widespread adoption of cheap, non-invasive diagnostic detection devices for coronaviruses – ones that look and function...
Marc Davis | September 1, 2020 |

A Topical Solution for Chronic Pain

Pain impedes the life of millions around the world, and the market for topical creams to treat this pain is growing at an accelerated rate as people choose to treat pain directly vs ingesting pain killers. Some analysts, such as those at Allied Market Research, project that ...
Jonathon Brown | May 2, 2022 |

Buzz on the Bullboards: The Cannabis Deal of a Lifetime?

(Image via Aphria Inc.) The fate of one of the biggest mergers in cannabis’ young history as a legal market will be decided tomorrow, when shareholders of Leamington ON-based licensed producer Aphria Inc. ( TSX: APHA , Forum ) vote on whet...
Stockhouse Editorial | April 28, 2021 |

Baudax Shares Rise as FDA Approves NDA for Its Non-Opioid Pain Medication

Shares of Baudax Bio traded more than 20% higher and set a new 52-week high price after reporting that the FDA approved the company's non-opioid ANJESO™ drug for management of moderate to severe pain. Specialty pharmaceutical company Baudax Bio Inc. (BXRX:N...
Streetwise Reports | February 24, 2020 |

Does Gold Really Care Whether Coronavirus Brings Us Deflation or Inflation?

One of the many bothering issues about the coronavirus crisis, is whether it will turn out to be inflationary or deflationary. What do both of these scenarios mean for gold ahead?
Arkadiusz Sieron | May 14, 2020 |

The Golden 'Moment of Truth' Is Upon Us: $1,400-Plus or Not?

With the precious metals markets range-bound and driven by forces beyond his control, sector expert Michael Ballanger turns his contrarian eye to the past. With gold enjoying its best week of the year, with the Daily Sentiment Index charging northward, with ...
Streetwise Reports | June 18, 2019 |

Buzz on the Bullboards: The Birth of a Cannabis Heavyweight

(Image via Tilray Inc.) Healthcare stocks were some of the most viewed and best performing across the Stockhouse Bullboards have been health care, though that sector has seen some cooling off, except where a few cannabis stories are concerned. While this trend h...
Stockhouse Editorial | May 5, 2021 |

FDA Approval of Biopharma's Pain Drug Expected This Year

The reasons a green light is anticipated and how it relates to the closing of Avenue Therapeutics' pending acquisition are discussed in an H.C. Wainwright & Co. report. In a Feb. 13 research note, H.C. Wainwright & Co. analyst Ed Arce reported that the U.S. ...
Streetwise Reports | February 20, 2020 |

Assertio Therapeutics' Shares Jump 50% on Sale of Shingles Pain Drug to Alvogen

Assertio Therapeutics' shares rose 50% today after the firm reported that it has agreed to sell all rights to its Gralise drug used in the treatment of pain from shingles to Alvogen for $127.5 million. The transaction is expected to close in January 2020. Shares of ph...
Streetwise Reports | December 13, 2019 |

Alder BioPharmaceuticals Shares Surge 80% on Acquisition News

Shares of migraine treatment research firm Alder BioPharmaceuticals opened 84% higher today after the company announced that it has agreed to be acquired by H. Lundbeck for $1.95 billion. Early this morning, clinical-stage biopharmaceutical company Alder BioPharmaceu...
Streetwise Reports | September 17, 2019 |
1 2 3 4 5 6 7 8 9 10 ...